BMEA

Biomea Fusion, Inc.
CAPPED RATING

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc. (BMEA) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.6
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -61.5%
Price Return 12M -59.7%
Catalyst Signal 0.00
Market Cap $37.8M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D (1.3) D- (0.8) D (1.3) C+ (2.6) D+ (1.7)
2026-11-10 C+ (2.5) D+ (1.8) C (2.5) C- (2.1) C+ (2.6) C (2.3)
2026-11-03 C+ (2.5) D+ (1.7) C+ (2.5) C- (1.9) C+ (2.7) C (2.3)
2026-10-27 C+ (2.5) D+ (1.8) C+ (2.5) D+ (1.7) C+ (2.6) C (2.2)
2026-10-20 C+ (2.5) D+ (1.8) C+ (2.5) C- (2.1) C+ (2.6) C (2.3)
Page 1 of 4